BridgeBio Pharma Inc.

31.17
-0.59 (-1.86%)
At close: Feb 11, 2025, 3:59 PM
31.14
-0.10%
After-hours Feb 11, 2025, 05:31 PM EST
undefined%
Bid 31
Market Cap 5.89B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.42
PE Ratio (ttm) -12.88
Forward PE n/a
Analyst Buy
Ask 31.58
Volume 1,080,007
Avg. Volume (20D) 2,537,226
Open 31.57
Previous Close 31.76
Day's Range 31.02 - 32.11
52-Week Range 21.62 - 41.04
Beta undefined

About BBIO

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-car...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2019
Employees 550
Stock Exchange NASDAQ
Ticker Symbol BBIO

Analyst Forecast

According to 12 analyst ratings, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is $46.5, which is an increase of 49.18% from the latest price.

Buy 91.67%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

BridgeBio Pharma Inc. is scheduled to release its earnings on Feb 24, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+16.1%
BridgeBio Pharma shares are trading higher after t... Unlock content with Pro Subscription
3 months ago
-5.74%
BridgeBio Pharma shares are trading lower after the company reported mixed Q3 financial results.